Search results
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
Motley Fool via Yahoo Finance· 5 hours agoWith that as a backdrop, here are three biotech stocks that are worth holding for years to come:...
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Zacks via Yahoo Finance· 2 hours agoEylea HD generated revenues of $200 million in the United States. Total revenues include...
Sanofi (NASDAQ:SNY) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoSanofi (NASDAQ:SNY) Q1 2024 Earnings Call Transcript April 25, 2024 Sanofi reports earnings inline with expectations. Reported EPS is $0.96 EPS,...
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks via Yahoo Finance· 3 hours agoAlthough the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the...
Sanofi Expected to Post Q2 2024 Earnings of $0.90 Per Share (NASDAQ:SNY)
ETF DAILY NEWS· 2 days agoSanofi (NASDAQ:SNY – Free Report) – Equities research analysts at Leerink Partnrs cut their Q2 2024 EPS estimates for shares of Sanofi in a report released ...
Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
Investor's Business Daily· 25 minutes agoThe Street projected a higher $10.18 per share. Revenue included $1.76 billion from the products...
Sanofi ADR (NASDAQ: SNY) Is Up 0.29% – Is It Capable Of A Rally? – Stocks Register
Stocks Register· 1 day agoSanofi ADR (NASDAQ:SNY) traded at $49.23 at close of the session on Tuesday, April 30, made an upward move of 0.29% on its previous day’s price. Looking at the stock we see ...
Diana Blankman
US News & World Report· 7 hours agoIn her current role at Sanofi, Diana leads US Corporate Social Responsibility, accountable for the development and implementation of the company’s social impact, employee ...
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings: Challenges and Opportunities Amidst ...
GuruFocus.com via Yahoo Finance· 4 hours agoAmong its key products are Eylea, approved for various eye diseases, and Dupixent, used in treating...
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 9 hours agoMerck & Co- $30.5bn Merck & Co’s revenues reached $60.1bn in FY 2023, with R&D investments peaking at $30.5bn. Displaying a staggering 126% growth over...
